ES2173187T3 - Sintesis de bibliotecas combinatoriales. - Google Patents

Sintesis de bibliotecas combinatoriales.

Info

Publication number
ES2173187T3
ES2173187T3 ES95926291T ES95926291T ES2173187T3 ES 2173187 T3 ES2173187 T3 ES 2173187T3 ES 95926291 T ES95926291 T ES 95926291T ES 95926291 T ES95926291 T ES 95926291T ES 2173187 T3 ES2173187 T3 ES 2173187T3
Authority
ES
Spain
Prior art keywords
synthesis
libraries
sub
producing
standard deviation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95926291T
Other languages
English (en)
Inventor
John J Baldwin
Eric G Horlbeck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacopeia LLC
Original Assignee
Pharmacopeia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacopeia Inc filed Critical Pharmacopeia Inc
Application granted granted Critical
Publication of ES2173187T3 publication Critical patent/ES2173187T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00277—Apparatus
    • B01J2219/0054—Means for coding or tagging the apparatus or the reagents
    • B01J2219/00572—Chemical means
    • B01J2219/00578—Chemical means electrophoric
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583—Features relative to the processes being carried out
    • B01J2219/00592—Split-and-pool, mix-and-divide processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00718—Type of compounds synthesised
    • B01J2219/0072—Organic compounds
    • B01J2219/00722—Nucleotides
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00718—Type of compounds synthesised
    • B01J2219/0072—Organic compounds
    • B01J2219/00725—Peptides
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00718—Type of compounds synthesised
    • B01J2219/0072—Organic compounds
    • B01J2219/00731—Saccharides
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/12—Libraries containing saccharides or polysaccharides, or derivatives thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Catalysts (AREA)
  • Inorganic Fibers (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)

Abstract

DIVIDIENDO DIRECTAMENTE LOS CONTENIDOS DE CADA SUBCOMBINACION POR LAS SUBCOMBINACIONES PARA EL SIGUIENTE PASO EN EL ESQUEMA SINTETICO PARA PRODUCIR UNA BIBLIOTECA COMBINATORIAL SE REDUCE LA DESVIACION ESTANDAR {SI}, RELATIVA A LA DESVIACION ESTANDAR DEL METODO DE SINTESIS DE DIVISION PARA PRODUCIR LAS BIBLIOTECAS.
ES95926291T 1994-06-22 1995-06-21 Sintesis de bibliotecas combinatoriales. Expired - Lifetime ES2173187T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/263,804 US5663046A (en) 1994-06-22 1994-06-22 Synthesis of combinatorial libraries

Publications (1)

Publication Number Publication Date
ES2173187T3 true ES2173187T3 (es) 2002-10-16

Family

ID=23003286

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95926291T Expired - Lifetime ES2173187T3 (es) 1994-06-22 1995-06-21 Sintesis de bibliotecas combinatoriales.

Country Status (10)

Country Link
US (1) US5663046A (es)
EP (1) EP0766826B1 (es)
JP (1) JPH10503755A (es)
AT (1) ATE217972T1 (es)
AU (1) AU688076B2 (es)
CA (1) CA2193064A1 (es)
DE (1) DE69526791T2 (es)
DK (1) DK0766826T3 (es)
ES (1) ES2173187T3 (es)
WO (1) WO1995035503A1 (es)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030215798A1 (en) * 1997-06-16 2003-11-20 Diversa Corporation High throughput fluorescence-based screening for novel enzymes
US5880972A (en) * 1996-02-26 1999-03-09 Pharmacopeia, Inc. Method and apparatus for generating and representing combinatorial chemistry libraries
US20040241759A1 (en) * 1997-06-16 2004-12-02 Eileen Tozer High throughput screening of libraries
US20050070005A1 (en) * 1997-06-16 2005-03-31 Martin Keller High throughput or capillary-based screening for a bioactivity or biomolecule
US20030054543A1 (en) * 1997-06-16 2003-03-20 Lafferty William Michael Device for moving a selected station of a holding plate to a predetermined location for interaction with a probe
US20020102598A1 (en) * 1997-06-16 2002-08-01 Lafferty William Michael Positioning system for moving a selected station of a holding plate to a predetermined location for interaction with a probe
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
AU767185B2 (en) 1998-03-23 2003-11-06 President And Fellows Of Harvard College Synthesis of compounds and libraries of compounds
WO2000031536A2 (en) * 1998-11-23 2000-06-02 President And Fellows Of Harvard College Detecting structural or synthetic information about chemical compounds
US6254835B1 (en) * 1999-03-31 2001-07-03 Pharmacopeia, Inc. Methods and apparatus for improved fluid control utilizing a u-valve employing a bidirectional check valve
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
WO2001059450A2 (en) 2000-02-08 2001-08-16 Sangamo Biosciences, Inc. Cells expressing zinc finger protein for drug discovery
US7923542B2 (en) 2000-04-28 2011-04-12 Sangamo Biosciences, Inc. Libraries of regulatory sequences, methods of making and using same
EP1276865B1 (en) 2000-04-28 2014-05-21 Sangamo BioSciences, Inc. Methods for binding an exogenous molecule to cellular chromatin
US6511808B2 (en) 2000-04-28 2003-01-28 Sangamo Biosciences, Inc. Methods for designing exogenous regulatory molecules
ATE374249T1 (de) 2000-04-28 2007-10-15 Sangamo Biosciences Inc Datenbanken von regulatorischen sequenzen, methoden zu ihrer herstellung und verwendung
AU2001257421A1 (en) 2000-04-28 2001-11-12 Sangamo Biosciences, Inc. Pharmacogenomics and identification of drug targets by reconstruction of signal transduction pathways based on sequences of accessible regions
EP1287364B1 (en) 2000-04-29 2008-10-22 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
EP2336166A1 (en) 2000-10-12 2011-06-22 University Of Rochester Compositions that inhibit proliferation of cancer cells
EP1343973B2 (en) 2000-11-16 2020-09-16 California Institute Of Technology Apparatus and methods for conducting assays and high throughput screening
US20030138782A1 (en) * 2001-01-19 2003-07-24 Evans Glen A. Computer-directed assembly of a polynucleotide encoding a target polypeptide
US6955888B2 (en) 2001-06-11 2005-10-18 Xenoport Methods of screening agents, conjugates or conjugate moieties for transport by a PEPT2 transporter
EP1401850A1 (en) 2001-06-20 2004-03-31 Nuevolution A/S Nucleoside derivatives for library preparation
DE10147074A1 (de) * 2001-09-25 2003-05-08 Beru Ag Verfahren zum Betreiben einer aus mehreren Heizelementen bestehenden mehrstufigen elektrischen Heizung
EP1572168B1 (en) 2002-02-06 2010-05-26 Vicor Technologies, Inc. Anti-infarction molecules
IL163822A0 (en) 2002-03-15 2005-12-18 Nuevolution As An improved method for synthesising templated molecules
WO2004013070A2 (en) * 2002-08-01 2004-02-12 Nuevolution A/S Multi-step synthesis of templated molecules
EP1575992A4 (en) 2002-08-05 2007-02-21 Univ Rochester CHIMERIC PROTEINS WITH PROTEIN TRANSDUCTION FIELD / DOMAINE DESAMINASE, ASSOCIATED COMPOUNDS AND CORRESPONDING USES
WO2004039825A2 (en) * 2002-10-30 2004-05-13 Nuevolution A/S Method for the synthesis of a bifunctional complex
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
BR0316737A (pt) 2002-11-27 2005-12-13 Irm Llc Métodos e composições para induzir apoptose em células cancerosas
AU2003291964A1 (en) * 2002-12-19 2004-07-14 Nuevolution A/S Quasirandom structure and function guided synthesis methods
CA2513722A1 (en) 2003-02-01 2004-08-19 Neuralab Limited Active immunization to generate antibodies to soluble a-beta
WO2004074429A2 (en) 2003-02-21 2004-09-02 Nuevolution A/S Method for producing second-generation library
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
EP1633189B1 (en) 2003-05-19 2017-07-05 Prothena Biosciences Limited Truncated fragments of alpha-synuclein in lewy body disease
US8153410B2 (en) 2003-07-07 2012-04-10 Fox Chase Cancer Center Alternate morpheein forms of allosteric proteins as a target for the development of bioactive molecules
US20060162014A1 (en) 2003-07-07 2006-07-20 Jaffe Eileen K Alternate morpheeins of allosteric proteins as a target for the development of bioactive molecules
EP1670939B1 (en) 2003-09-18 2009-11-04 Nuevolution A/S A method for obtaining structural information concerning an encoded molecule and method for selecting compounds
SG149039A1 (en) 2003-12-17 2009-01-29 Elan Pharm Inc Ass IMMUNOGENIC PEPTIDE CARRIER CONJUGATES AND METHODS OF PRODUCING SAME
TWI355390B (en) 2003-12-17 2012-01-01 Wyeth Llc Immunogenic peptide carrier conjugates and methods
WO2005078122A2 (en) * 2004-02-17 2005-08-25 Nuevolution A/S Method for enrichment involving elimination by mismatch hybridisation
US7572600B2 (en) 2004-08-04 2009-08-11 Chemocentryx, Inc. Enzymatic activities in chemokine-mediated inflammation
MX2007001679A (es) 2004-08-09 2007-05-23 Elan Pharm Inc Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica.
WO2006018277A1 (en) * 2004-08-17 2006-02-23 Universität Bern Method for rational combinatorial synthesis
JP2008529536A (ja) 2005-02-14 2008-08-07 ユニバーシティー オブ アイオワ リサーチ ファウンデーション 加齢性黄斑変性を処置および診断するための方法および試薬
EP2631652A1 (en) 2005-04-05 2013-08-28 Corning Incorporated Label free biosensor
ES2431315T3 (es) 2005-05-19 2013-11-26 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Epítopos funcionales del antígeno PsaA de Streptococcus pneumoniae y usos de los mismos
US8193328B2 (en) 2005-09-08 2012-06-05 Philadelphia Health & Education Corporation Identification of modulators of serine protease inhibitor Kazal and their use as anti-cancer and anti-viral agents
CA2625891A1 (en) 2005-10-14 2007-04-26 Carlton D. Donald Inhibition of pax2 by defb1 induction as a therapy for cancer
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
LT2336315T (lt) 2005-12-01 2017-11-10 Nuevolution A/S Fermentiniai kodavimo būdai, skirti efektyviai didelių bibliotekų sintezei
EP2035448A4 (en) 2006-06-01 2010-11-03 Elan Pharm Inc NEUROACTIVE FRAGMENTS OF APP
EP2560001B1 (en) 2006-09-21 2016-04-13 University of Rochester Compositions and methods related to protein displacement therapy for myotonic distrophy
US8999317B2 (en) 2006-11-01 2015-04-07 University Of Rochester Methods and compositions related to the structure and function of APOBEC3G
CA2674378A1 (en) 2007-01-03 2008-07-17 Burnham Institute For Medical Research Methods and compositions related to clot binding compounds
WO2008098182A1 (en) 2007-02-08 2008-08-14 University Of Utah Research Foundation Methods and compositions related to inhibition of viral entry
EP2118300B1 (en) 2007-02-23 2015-05-27 Prothena Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
HUE043966T2 (hu) 2007-02-23 2019-09-30 Prothena Biosciences Ltd Szinukleinopátiás és amiloidogén betegség megelõzése és kezelése
WO2009078799A1 (en) 2007-12-17 2009-06-25 Marfl Ab New vaccine for the treatment of mycobacterium related disorders
KR101603076B1 (ko) 2007-12-28 2016-03-14 프로테나 바이오사이언시즈 리미티드 아밀로이드증의 치료 및 예방
CA2713423A1 (en) 2008-01-18 2009-07-23 North Carolina State University Peptides and methods of use as therapeutics and screening agents
US8816095B2 (en) * 2008-08-15 2014-08-26 Georgetown University Na channels, disease, and related assays and compositions
WO2010021415A1 (en) 2008-08-18 2010-02-25 Seoul National University Industry Foundation Method for controlling cancer metastasis or cancer cell migration by modulating the cellular level of lysyl trna synthetase
US20120070443A1 (en) 2008-12-02 2012-03-22 University Of Utah Research Foundation Pde1 as a target therapeutic in heart disease
CA2745266C (en) 2008-12-03 2018-04-10 Yue Xu Stem cell cultures
US20120190574A1 (en) 2009-06-19 2012-07-26 The Arizona Board of Regents, A body Corporate of the State of Arizona for and on behalf of Arizona Compound Arrays for Sample Profiling
WO2011022502A1 (en) 2009-08-18 2011-02-24 Georgetown University Boronic acid compositions and methods related to cancer
JP2013507365A (ja) 2009-10-07 2013-03-04 サンフォード−バーナム メディカル リサーチ インスティテュート 血餅結合脂質化合物に関する方法および組成物
CA2784145A1 (en) 2009-12-18 2011-06-23 Sanford-Burnham Medical Research Institute Methods and compositions related to clot-binding compounds
SI2558577T1 (sl) 2010-04-16 2019-05-31 Nuevolution A/S Bifunkcionalni kompleksi in metode za pripravo in uporabo takšnih kompleksov
CA2868735C (en) 2011-03-28 2020-02-25 University Of Utah Research Foundation D-peptide conjugates comprising a membrane localizing potency-enhancing cargo molecule for inhibiting hiv entry
WO2012162514A2 (en) 2011-05-26 2012-11-29 Regents Of The University Of Michigan Epigenetic co-repressors of the gamma-globin gene and methods of using same
WO2013043012A2 (en) 2011-09-22 2013-03-28 Medicinal Bioconvergence Research Center Novel use of leucyl trna synthetase
WO2013044029A1 (en) 2011-09-23 2013-03-28 University Of Louisville Research Foundation, Inc. Methods and compositions for expanding cells and improving engraftment
KR101398079B1 (ko) 2011-10-10 2014-05-27 재단법인 의약바이오컨버젼스연구단 글리실-티알엔에이 합성효소 및 캐드헤린을 이용한 암 예방 또는 치료제의 스크리닝 방법
WO2013078138A1 (en) 2011-11-21 2013-05-30 OSI Pharmaceuticals, LLC Proton nmr spectroscopy for biochemical screening
US9970932B2 (en) 2013-03-15 2018-05-15 Arizona Board Of Regents On Behalf Of Arizona State University Non-covalent patterned chemical features and use thereof in MALDI-based quality control
US10006919B2 (en) 2013-03-15 2018-06-26 Arizona Board Of Regents On Behalf Of Arizona State University Peptide array quality control
US11142577B2 (en) 2014-09-12 2021-10-12 The Board Of Trustees Of The Leland Stanford Junior University WNT signaling agonist molecules
WO2016100857A1 (en) 2014-12-19 2016-06-23 Regeneron Pharmaceuticals, Inc. Stem cells for modeling type 2 diabetes
JP2018513166A (ja) 2015-04-20 2018-05-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 系統的な探索、成熟化および伸長プロセスにより同定した、タンパク質に対する特異的ペプチドバインダー
US10758886B2 (en) 2015-09-14 2020-09-01 Arizona Board Of Regents On Behalf Of Arizona State University Conditioned surfaces for in situ molecular array synthesis
WO2017208210A1 (en) 2016-06-03 2017-12-07 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2017223116A2 (en) 2016-06-20 2017-12-28 Healthtell Inc. Methods for differential diagnosis of autoimmune diseases
CN109790203A (zh) 2016-06-20 2019-05-21 健康之语公司 自身免疫疾病的诊断和治疗方法
EP3482210B1 (en) 2016-07-06 2021-06-23 Prothena Biosciences Limited Assay for detecting total and s129 phosphorylated alpha-synuclein
EP3490373B1 (en) 2016-07-29 2023-10-25 Regeneron Pharmaceuticals, Inc. Mice comprising mutations resulting in expression of c-truncated fibrillin-1
CA3038846A1 (en) 2016-10-12 2018-04-19 Janssen Biotech, Inc. Methods for screening for modulators of gdf15-like biological activity
US11371990B2 (en) 2016-11-11 2022-06-28 Cowper Sciences Inc. Methods for identifying candidate biomarkers
EP3619534A1 (en) 2017-05-05 2020-03-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Microtubule-targeting drugs as immune checkpoint inhibitors and methods of screening novel immune checkpoint inhibitors for the treatment of cancers and infectious diseases
WO2019055618A1 (en) 2017-09-15 2019-03-21 Arizona Board Of Regents On Behalf Of Arizona State University METHODS OF CLASSIFYING RESPONSES TO ANTICANCER IMMUNOTHERAPY
KR102444458B1 (ko) 2017-11-10 2022-09-19 리제너론 파마슈티칼스 인코포레이티드 Slc30a8 돌연변이를 포함하는 비인간 동물 및 사용 방법
EP3823979A1 (en) 2018-07-20 2021-05-26 AiCuris GmbH & Co. KG Methods for screening and identifying agents that inhibit or modulate the nuclear egress complex of herpesviruses
CN113966401A (zh) 2019-04-10 2022-01-21 犹他大学研究基金会 用于治疗amd的htra1调节
WO2021067550A1 (en) 2019-10-02 2021-04-08 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for identifying neoantigens for use in treating and preventing cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650489A (en) * 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
US5541061A (en) * 1992-04-29 1996-07-30 Affymax Technologies N.V. Methods for screening factorial chemical libraries

Also Published As

Publication number Publication date
AU688076B2 (en) 1998-03-05
EP0766826B1 (en) 2002-05-22
JPH10503755A (ja) 1998-04-07
DE69526791T2 (de) 2003-01-02
US5663046A (en) 1997-09-02
DK0766826T3 (da) 2002-07-15
AU3009595A (en) 1996-01-15
CA2193064A1 (en) 1995-12-28
ATE217972T1 (de) 2002-06-15
DE69526791D1 (de) 2002-06-27
EP0766826A1 (en) 1997-04-09
EP0766826A4 (en) 1998-02-11
WO1995035503A1 (en) 1995-12-28

Similar Documents

Publication Publication Date Title
ES2173187T3 (es) Sintesis de bibliotecas combinatoriales.
NO982787L (no) FremgangsmÕte for fremstilling av syntesegass
ES2174075T3 (es) Librerias combinatorias de compuestos bioquimicos marcados y metodos para producir las mismas.
ZA962434B (en) Process for the production of combinatorial compound libraries
NO983694D0 (no) Omformingssystem for hydrokarbongass og fremgangsmåte for fremstilling av syntetisk hydrokarbon
DE69634127D1 (de) Zellfreie synthese von polyketiden
NO961387L (no) Fremgangsmåte for fremstilling av en Fischer-Tropsch-katalysator
DE69611442T2 (de) Enzymatische synthese von glykosidischen verbindungen
PT773224E (pt) Proceso para a sintese selectiva de disulfuretos de sililalquilo
NO962926D0 (no) Fremgangsmåte for fremstilling av en katalysator, katalysator oppnådd derved samt fremgangsmåte for syntese av hydrokarboner
DE69022337D1 (de) 2-Stufenverfahren zur Synthese von Kohlenwasserstoffen.
DE69603837D1 (de) Behälter für Chlorobutanol enthaltende Pharmazeutika
PT1015466E (pt) Derivados 9-hidrazona e 9-azina da eritromicina e processo para a sua producao
FR2638157B1 (fr) Procede de production d'alkylbenzenes utilisant un catalyseur a base de mordenite modifiee
NO951068L (no) System for produksjon av hydrokarboner
NO964748D0 (no) Fremgangsmåte for omdanning av en syntesegass til hydrokarboner
NO964495D0 (no) Fremgangsmåte for generering av objekt-adaptivt kodeblokkmönster
NO962186D0 (no) Fremgangsmåte for fremstilling av kombinatoriske forbindelsesbiblioteker
IT1265119B1 (it) Procedimento di produzione di fenilalcani utilizzante un catalizzatore a base di zeolite y modificata
NO962930D0 (no) Fremgangsmåte for omdannelse av en syntesegass til en flytende fase
IS4038A (is) Aðferð til að framleiða olíukennda blöndu
WO1997008190A3 (en) Compounds
DE69326126D1 (de) Zeitverschiebung zur Kodierung von Analyse durch Synthese
ITMI950544A0 (it) Metodo per la produzione di baderne per tenute a premistoppa
DK0855365T3 (da) Fremgangsmåde til fremstilling af syntesegas

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 766826

Country of ref document: ES